4D Molecular Therapeutics Balans Gezondheid
Financiële gezondheid criteriumcontroles 6/6
4D Molecular Therapeutics has a total shareholder equity of $588.3M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $620.1M and $31.8M respectively.
Belangrijke informatie
0%
Verhouding schuld/eigen vermogen
US$0
Schuld
| Rente dekkingsratio | n/a |
| Contant | US$541.95m |
| Aandelen | US$588.34m |
| Totaal verplichtingen | US$31.78m |
| Totaal activa | US$620.12m |
Recente financiële gezondheidsupdates
4D Molecular Therapeutics (NASDAQ:FDMT) Is In A Good Position To Deliver On Growth Plans
Aug 10
We're Not Very Worried About 4D Molecular Therapeutics' (NASDAQ:FDMT) Cash Burn Rate
Nov 08Here's Why We're Watching 4D Molecular Therapeutics' (NASDAQ:FDMT) Cash Burn Situation
May 08We're Keeping An Eye On 4D Molecular Therapeutics' (NASDAQ:FDMT) Cash Burn Rate
Sep 29Here's Why We're Watching 4D Molecular Therapeutics' (NASDAQ:FDMT) Cash Burn Situation
Jun 11Recent updates
4D Molecular Therapeutics: Market Expects Wet AMD Gene Therapy Failure - I'm Not So Sure
Oct 044D Molecular Therapeutics (NASDAQ:FDMT) Is In A Good Position To Deliver On Growth Plans
Aug 104D Molecular Therapeutics: R100 Vector Pushes Forward To Bring Q4 Of 2024 DME Data
Jul 194D Molecular Therapeutics: Catalysts With Pioneering Gene Therapy With Directed Evolution
Apr 294D Molecular Therapeutics Advances Wet AMD Treatment Paradigm
Feb 064D Molecular Therapeutics: Several Value Inflection Points To Watch In 2024
Jan 254D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Just Reported And Analysts Have Been Cutting Their Estimates
Nov 12We're Not Very Worried About 4D Molecular Therapeutics' (NASDAQ:FDMT) Cash Burn Rate
Nov 08Here's Why We're Watching 4D Molecular Therapeutics' (NASDAQ:FDMT) Cash Burn Situation
May 08We're Keeping An Eye On 4D Molecular Therapeutics' (NASDAQ:FDMT) Cash Burn Rate
Sep 294D Molecular Therapeutics GAAP EPS of -$0.87, revenue of $0.16M
Aug 11Here's Why We're Watching 4D Molecular Therapeutics' (NASDAQ:FDMT) Cash Burn Situation
Jun 11Analyse van de financiële positie
Kortlopende schulden: FDMT's short term assets ($552.6M) exceed its short term liabilities ($19.4M).
Langlopende schulden: FDMT's short term assets ($552.6M) exceed its long term liabilities ($12.4M).
Schuld/ eigen vermogen geschiedenis en analyse
Schuldniveau: FDMT is debt free.
Schuld verminderen: FDMT has not had any debt for past 5 years.
Balans
Analyse van de cashflow
Voor bedrijven die in het verleden gemiddeld verliesgevend zijn geweest, beoordelen we of ze ten minste 1 jaar kasstroom hebben.
Stabiele cash runway: FDMT has sufficient cash runway for more than 3 years based on its current free cash flow.
Voorspelling contante baan: FDMT has sufficient cash runway for 2.5 years if free cash flow continues to reduce at historical rates of 21.7% each year.